

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

PART I

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 30TH SEPTEMBER, 2013

	Unaudited					(Rs. lakhs)
	3 months ended 30.09.2013	Preceding 3 months ended 30.06.2013	Corresponding 3 months ended 30.09.2012	9 months ended 30.09.2013	9 months ended 30.09.2012	Audited Year ended 31.12.2012
Income from Operations						
Net Sales (net of excise duty)	62054	63686	66850	188954	194324	259993
Other Operating Income (net of expenses relating to service income)	611	851	680	1936	2100	2650
Total Income from Operations (net)	62665	64537	67530	190890	196424	262643
Expenses						
Cost of materials consumed	14912	13660	14018	39878	34510	43781
Purchases of stock-in-trade	20379	11722	16121	50764	43242	60745
Changes in inventories of finished goods, work-in-progress and stock-in-trade	(7806)	4195	(1672)	(6242)	4001	5259
Total materials consumed	27485	29577	28467	84400	81753	109785
Employee benefits expense	9509	9911	7471	27328	21857	29551
Depreciation	496	498	484	1411	1326	1784
Other expenses	15244	14128	12067	42067	34200	46319
Expenses relating to service income	(979)	(1295)	(1046)	(3289)	(3228)	(4539)
Total operating expenses	24270	23242	18976	67517	54155	73115
Total expenses	51755	52819	47443	151917	135908	182900
Profit from Operations before Other Income and Exceptional Items	10910	11718	20087	38973	60516	79743
Other Income	3937	3685	4107	15318	15520	19735
Profit from ordinary activities before Exceptional Items	14847	15403	24194	54291	76036	99478
Exceptional Items	(77)	2007	(1655)	1774	(11853)	(14822)
Profit from ordinary activities before tax	14770	17410	22539	56065	64183	84656
Tax Expense	4675	5906	7305	17565	20308	26930
Net Profit from ordinary activities	10095	11504	15234	38500	43875	57726
Paid-up Equity Share Capital (Face value per share Rs. 10)	8470	8470	8470	8470	8470	8470
Reserves excluding Revaluation Reserves						192531
Earnings Per Share (EPS) (of Rs. 10 each) (not annualised)						
Basic and diluted EPS (Rs.)	11.9	13.5	18.0	45.5	51.8	68.2
PART II						
A. PARTICULARS OF SHAREHOLDING						
Public Shareholding						
Number of shares	41785529	41785529	41785529	41785529	41785529	41785529
Percentage of shareholding	49.3%	49.3%	49.3%	49.3%	49.3%	49.3%
Promoters and promoter group Shareholding						
(a) Pledged/Encumbered						
- Number of shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
(b) Non-encumbered						
- Number of shares	42917488	42917488	42917488	42917488	42917488	42917488
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%	100%	100%	100%
- Percentage of shares (as a % of the total share capital of the company)	50.7%	50.7%	50.7%	50.7%	50.7%	50.7%

Particulars	3 months ended 30.09.2013
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	-
Received during the quarter	10
Disposed of during the quarter	10
Remaining unresolved at the end of the quarter	-

- The quarter ended 30th September, 2013 saw the impact of introduction of the revamped Price Control Order, extending coverage to the National List of Essential Medicines (NLEM). The quarter was also impacted by a segment of the trade not buying the company's products and supply constraints.
- The Company has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.
- The above Results were reviewed by the Audit Committee and were thereafter approved by the Board of Directors at their respective meetings held on 11th November, 2013.
- The statutory auditors have carried out a limited review of the standalone results for the quarter ended 30th September 2013.
- The figures for 2012 have been regrouped wherever necessary to facilitate comparison.

By Order of the Board

M. B. Kapadia
Senior Executive Director

11th November, 2013